Challenge assumptions and reset expectations when it comes to pre-launch SG&A investment to increase the odds of commercial success.
Scott Coons
Advertisement
Launch Manager, Commercial Advisory Group, Syneos Health Consulting
Articles by Scott Coons
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Bayer’s Lynkuet as First Dual Neurokinin Antagonist for Menopausal Hot Flashes
2
TrumpRx and the Dawn of Direct-to-Consumer Commercialization
3
AI Becomes Pharma’s New Operating System: Q&A with causaLens’ CEO and Co-Founder Darko Matovski
4
Pharmaceutical Executive Daily: TrumpRx's Implication on DTC Commercialization
5
